FDA to Zeltia: NO – An FDA advisory committee has handed Spain’s Zeltia a crushing blow, deciding against a combination therapy that includes its lead cancer drug Yondelis (trabectedin) by a vote of 14 to 1. The news cost Zeltia 35 percent of its share price…more
FDA to Shire: Fast-track – Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type I Gaucher disease…more
Pfizer: We want to be #3! – Pfizer Inc. plans for its worldwide sales of medicines for treating cancer to increase 10-fold by 2018, said Andreas Penk, regional president of the company’s cancer business in Europe. Pfizer, the world’s biggest drugmaker, had about $2.5 billion in cancer-medicine sales in 2008, according to the company. Pfizer plans to become the third-largest maker of cancer treatments, up from about seventh now…more
Daiichi chief talks about Effient.
Med Device firms and Kickbacks – Several large medical device companies have been accused of marketing their products for unapproved uses while charging the federal government, according to documents unsealed in Houston federal court…more
PLUS – What if I was to go back into Pharma Sales?
AND – some recent stats on physicians on-line (globally). Pretty big. And while we’re at pretty big, here is the horrendous tangle that could be the future of healthcare here in the U.S.
———-
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply